Lipoglycopeptide
Staphylococcus aureus (including Methicillin-resistant isolates), Coagulase-negative Staphylococci, Streptococcus pneumoniae, Streptococcus viridans group, Enterococcus spp. (including some vancomycin-resistant isolates), Corynebacterium spp.
Telavancin inhibits bacterial cell wall biosynthesis by interfering with peptidoglycan production, and also causes depolarization of bacterial membrane
Combination of both concentration-dependent effects (Cpeak:MIC) and AUC:MIC ratio
Healthy volunteers given 7.5mg/kg/day at steady state – Cmax: mean of 96.7mg/L; Half-life: mean of 8.83h; Volume of distribution: mean of 105ml/kg
Skin: Red man’s syndrome
CNS: Headache, dizziness
GI: nausea, vomiting
Cardiac: QT prolongation
Metabolic: Hypokalemia
Kidney: Increased serum creatinine
Otic: Tinnitus, transient hearing loss
Other: Taste disturbance (metallic or soap)
Not commercially available. Phase II/III studies for cSSI have evaluated daily doses of 7.5mg/kg and 10mg/kg. One phase III study for hospital acquired pneumonia studied daily doses of 10mg/kg.
Not determined, however phase II and phase III studies have recommended dosage adjustments in patients with renal insufficiency, yet without recommendations for adjustments in hepatic insufficiency.
Not yet formally established. It is known however that telavancin prolongs the QT interval
Current speculation exists regarding black box warning for pregnancy
Limited data. No clinical significant interaction with aztreonam or piperacillin/tazobactam
Unknown – potential for black boxed warning when released due to lack of data.
Data are limited, however at present:
Efficacy/Toxicity: Serum creatinine
Brand name to be determined/Theravance, Inc.